Safety and efficacy comparisons of rituximab biosimilars to the reference product in patients with cancer: a systematic meta-analysis review

IF 1 Q4 PHARMACOLOGY & PHARMACY
Nina K. Song BPharm (Hons), Hala Musa BSc (Hons), MSc, MPharm, Michael Soriano BS Pharmacy (PH), Mellissa Batger BSc, MPharm, Bryson Hawkins BPharm (Hons), Iqbal Ramzan Dip Pharmacy (NZ), MSc, PhD (USyd), David E. Hibbs BSc (Hons), PhD, Grad Cert Ed (Higher Ed), Jennifer A. Ong BPharm (Hons), PhD, Grad Cert Ed Studies(Higher Ed)
{"title":"Safety and efficacy comparisons of rituximab biosimilars to the reference product in patients with cancer: a systematic meta-analysis review","authors":"Nina K. Song BPharm (Hons),&nbsp;Hala Musa BSc (Hons), MSc, MPharm,&nbsp;Michael Soriano BS Pharmacy (PH),&nbsp;Mellissa Batger BSc, MPharm,&nbsp;Bryson Hawkins BPharm (Hons),&nbsp;Iqbal Ramzan Dip Pharmacy (NZ), MSc, PhD (USyd),&nbsp;David E. Hibbs BSc (Hons), PhD, Grad Cert Ed (Higher Ed),&nbsp;Jennifer A. Ong BPharm (Hons), PhD, Grad Cert Ed Studies(Higher Ed)","doi":"10.1002/jppr.1827","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>To compare the efficacy and safety of rituximab biosimilars to reference rituximab in patients with cancer.</p>\n </section>\n \n <section>\n \n <h3> Data Sources</h3>\n \n <p>A systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. MEDLINE, EMBASE, and Cochrane Central databases were searched from inception to 12 January 2022 to obtain all randomised control trial (RCTs) reporting on the safety and efficacy outcomes of patients with cancer treated with rituximab biosimilars.</p>\n </section>\n \n <section>\n \n <h3> Study Selection</h3>\n \n <p>All RCTs comparing the reference rituximab with a biosimilar, conducted in inpatient and outpatient settings, were included in the systematic review.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Twenty-nine RCTs were identified to report on patients treated with rituximab. The odds of achieving overall response rate in patients treated with a rituximab biosimilar compared to the reference over at least 24 weeks of treatment was 1.06 (95% confidence interval [CI] 0.88–1.26). The proportion of patients experiencing any treatment emergent adverse events were comparable between the two study arms (OR 1.20 [95% CI 0.98–1.49]).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Biosimilars for rituximab have comparable efficacy and safety profiles in treatment naïve patients; however, evidence for efficacy and safety of switching patients from reference biologic to biosimilar is lacking, and further research is required.</p>\n </section>\n </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"52 5","pages":"332-356"},"PeriodicalIF":1.0000,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1827","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Practice and Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jppr.1827","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Aim

To compare the efficacy and safety of rituximab biosimilars to reference rituximab in patients with cancer.

Data Sources

A systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. MEDLINE, EMBASE, and Cochrane Central databases were searched from inception to 12 January 2022 to obtain all randomised control trial (RCTs) reporting on the safety and efficacy outcomes of patients with cancer treated with rituximab biosimilars.

Study Selection

All RCTs comparing the reference rituximab with a biosimilar, conducted in inpatient and outpatient settings, were included in the systematic review.

Results

Twenty-nine RCTs were identified to report on patients treated with rituximab. The odds of achieving overall response rate in patients treated with a rituximab biosimilar compared to the reference over at least 24 weeks of treatment was 1.06 (95% confidence interval [CI] 0.88–1.26). The proportion of patients experiencing any treatment emergent adverse events were comparable between the two study arms (OR 1.20 [95% CI 0.98–1.49]).

Conclusion

Biosimilars for rituximab have comparable efficacy and safety profiles in treatment naïve patients; however, evidence for efficacy and safety of switching patients from reference biologic to biosimilar is lacking, and further research is required.

Abstract Image

利妥昔单抗生物类似药与参考产品在癌症患者中的安全性和有效性比较:一项系统荟萃分析综述
目的比较利妥昔单抗生物类似药与利妥昔单抗对照药在肿瘤患者中的疗效和安全性。根据PRISMA指南进行系统评价和荟萃分析。检索MEDLINE、EMBASE和Cochrane Central数据库,从建立到2022年1月12日,获取所有报告利妥昔单抗生物类似药治疗癌症患者安全性和有效性结果的随机对照试验(rct)。所有在住院和门诊环境中进行的比较参考利妥昔单抗和生物仿制药的随机对照试验都被纳入系统评价。结果29项随机对照试验报告了利妥昔单抗治疗的患者。与对照组相比,接受利妥昔单抗生物类似药治疗的患者在至少24周的治疗中获得总缓解率的几率为1.06(95%可信区间[CI] 0.88-1.26)。两个研究组中出现任何治疗紧急不良事件的患者比例具有可比性(OR 1.20 [95% CI 0.98-1.49])。结论利妥昔单抗生物仿制药治疗naïve患者具有相当的疗效和安全性;然而,缺乏将患者从参考生物制剂转为生物类似药的有效性和安全性的证据,需要进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmacy Practice and Research
Journal of Pharmacy Practice and Research Health Professions-Pharmacy
CiteScore
1.60
自引率
9.50%
发文量
68
期刊介绍: The purpose of this document is to describe the structure, function and operations of the Journal of Pharmacy Practice and Research, the official journal of the Society of Hospital Pharmacists of Australia (SHPA). It is owned, published by and copyrighted to SHPA. However, the Journal is to some extent unique within SHPA in that it ‘…has complete editorial freedom in terms of content and is not under the direction of the Society or its Council in such matters…’. This statement, originally based on a Role Statement for the Editor-in-Chief 1993, is also based on the definition of ‘editorial independence’ from the World Association of Medical Editors and adopted by the International Committee of Medical Journal Editors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信